Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme. The clinical a
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-02-26 7:00 AM EST | Optimi Health Corp.
Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit therapieresistenter Depression (TRD) unter dem Authorised Prescriber Scheme mit den natürlich gewonnenen 5-mg-Psilocybin-Kapseln d
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-02-26 7:00 AM EST | Optimi Health Corp.
Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health
Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18t
2026-02-25 8:00 AM EST | Izotropic Corporation
Aleen Inc. Advances Personal Account Infrastructure Following AI Agent Development
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces continued internal progress in strengthening its Personal Account infrastructure following the previously announced development of Wellness AI Agents. Building on its AI agent framework, Aleen Inc. is optimizing the integration of these assistive tools within the Personal Account environment. Current improvements focus on enhancing internal system performance, increas
2026-02-25 8:00 AM EST | Aleen Inc.
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.
Biotechnologies, Cannabis, Santé, Producteurs de cannabis
2026-02-25 7:27 AM EST | Cardiol Therapeutics Inc.
Scryb Reports Positive Q1 2026: Cash Increased 50%, Liabilities Down 27%, Remains Largest Shareholder of Cybeats
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal quarter ended December 31, 2025 ("Q1 2026"). The filings are available on SEDAR+. Q1 2026 Highlights Cash position improved by 50% to $1.2 million (from $0.8 million at September 30, 2025), with working capital rising 6
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-02-25 7:01 AM EST | Scryb Inc.
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aime
Biotechnologies, Pharmaceutique, Santé
2026-02-25 3:00 AM EST | PreveCeutical Medical Inc.
Adia Med of Winter Park Expands into Cosmetics Due to High Patient Demand - Now Interviewing Nurse Practitioners for Hair Growth and Aesthetic Procedures
Winter Park, Florida--(Newsfile Corp. - February 24, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative wellness solutions through its subsidiary Adia Med, today announced that its Winter Park clinic is actively interviewing candidates for a Nurse Practitioner position specializing in cosmetic treatments, including advanced hair growth therapies.
Soins de santé et hôpitaux, Santé
2026-02-24 8:30 AM EST | Adia Nutrition Inc.
Functional Brands Inc. (MEHA), Launches www.Tru2u.health, a Digital Health Platform Delivering Peptides, GLP-1 Based Care with Board-Certified Telehealth Support and Clean Supplements
Lake Oswego, Oregon--(Newsfile Corp. - February 24, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the official launch of www.Tru2u.health, a digital health platform dedicated to helping individuals achieve their health goals through medication-based treatment, clean supplementation, and clinically guided wellness solutions. "Tru2u.health
Produits ménagers / de consommation / cosmétiques, Santé
2026-02-24 8:00 AM EST | Functional Brands Inc.
QScreen AI Advances Structured Commercial Discussions Following Canadian Trade Mission to Mexico
Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - QScreen AI Inc (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening and employee wellness, today provided an update on its participation in the official Government of Canada Trade Mission to Mexico, reporting substantive commercialization discussions with senior institutional and enterprise stakeholders as part of its broader North American growth strategy. Building on
2026-02-23 7:00 AM EST | QScreen AI Inc.
Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform
Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company focused on innovative drug delivery solutions, today provided an update on its ongoing cannabinoid research initiatives and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform. Independent research led by colleagues Dr. Patrick Neary of the Faculty
2026-02-23 6:12 AM EST | Rapid Dose Therapeutics Corp.
DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics for ophthalmic conditions, today announced that it has entered into a Letter of Intent ("LOI") with Hanson Instruments Ltd. (trading as Hanson Medical), a United Kingdom-based supplier of ophthalmic and optometric equipment, to exclusively explore a commercial partnership for the TeaRx™ dr
2026-02-20 5:00 PM EST | DiagnosTear Technologies Inc.
Jones Healthcare Group Wins Best of Show and Best in Class Honours at PAC Global Awards for Qube(TM) Eco
London, Ontario--(Newsfile Corp. - February 20, 2026) - As healthcare systems face increasing pressure to reduce waste and carbon impact, packaging innovation must deliver measurable results without compromising patient safety or pharmacy workflow. At the same time, environmental claims across industries are under greater scrutiny, with regulators, retailers and consumers demanding proof over promise. At the 2026 PAC Global Awards ceremony, held February 18-19 in Toronto, Jones Healthca
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-02-20 12:36 PM EST | Jones Healthcare Group
Apolo V Acquisition Corp. Amendment to Definitive Agreement with TelyRx, Inc. and Rescheduling of Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo V" or the "Company") announces it has amended its business combination agreement with TelyRx, Inc. ("TelyRx") dated January 19, 2026 (the "Business Combination Agreement") effected in connection with its previously announced proposed qualifying transaction (the "Qualifying Transaction") and postponed its special meeting of shareholders (the "Meeting
Soins de santé et hôpitaux, Santé
2026-02-20 12:10 PM EST | TelyRx
Edison Issues Report on Custodian Property Income REIT (CREI)
London, United Kingdom--(Newsfile Corp. - February 20, 2026) - Edison issues report on Custodian Property Income REIT (LSE: CREI) Custodian Property Income REIT (CREI) has completed the £36m corporate acquisition of a highly complementary, diversified family-owned portfolio (Grove Court Properties), which is its second such transaction in the past nine months. The acquisition has been financed by the issuance to the vendor of new CREI shares (75%) on an adjusted NAV for NAV basis a
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-02-20 10:29 AM EST | Edison Group
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-02-19 7:00 AM EST | Phio Pharmaceuticals Corp.
Rejuvenate Muscle Health(TM) Nears 10,000 Points of Distribution as Major U.S. Retailer Expands Functional Beverage Breakout by 2,105 Stores
Burlington, Ontario--(Newsfile Corp. - February 19, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announced today that a major U.S. retail partner will expand Rejuvenate Muscle Health™ into an additional 2,105 stores, with rollout set for mid May 2026. The expansion pushes the total number of North American points of distribution very near 10,000 points of distribution, marking a significant milestone in scale for the fa
Aliments / boissons, Sports, Santé
2026-02-19 7:00 AM EST | Promino Nutritional Sciences, Inc.
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards hergestellten natürlichen 5-mg-Psilocybin-Kapseln nach Australien bekannt. Diese werden zur Behandlung von Patientinnen und Patiente
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-02-19 2:00 AM EST | Optimi Health Corp.